Quick Facts

• Chronic Heart Failure (Mild-to-Severe): May be used to support patient condition, often in combination with other established treatments.
• High Blood Pressure (Hypertension): Used for the management of essential hypertension.
• Left Ventricular Dysfunction Post-Myocardial Infarction: Administered to stable patients following a heart attack to assist in cardiovascular management.

---

Карведилол is a prescription medication utilized for the management of specific cardiovascular conditions. Its primary therapeutic applications are focused on addressing three distinct medical domains.

For patients with mild to severe chronic heart failure, the medication is prescribed to help manage the condition, and is typically administered alongside diuretics, ACE inhibitors, and digitalis. Its use is associated with a potential to reduce the risk of hospitalization for heart failure.

The drug is also indicated for the management of essential hypertension, which is also known as high blood pressure. It may be used as a monotherapy or in combination with other antihypertensive agents to help maintain blood pressure within a target range.

Finally, Карведилол is used in clinically stable patients who have survived the acute phase of a myocardial infarction (heart attack) and present with left ventricular dysfunction. In this context, it is prescribed to support long-term cardiovascular outcomes.

Carvedilol eligibility is strictly defined by regulatory bodies based on age, physiological status, and pre-existing medical conditions. The medicine is approved for use in most adults for established cardiovascular indications. Older adults are generally eligible, though initial dosing may be lower.

Absolute Contraindications

Official labeling strictly prohibits the use of Carvedilol in patients with:

• Severe Liver Disease (hepatic impairment).
• Bronchial Asthma or related bronchospastic conditions.
• Cardiogenic Shock or Decompensated Heart Failure requiring intravenous support.
• Second or Third Degree AV Heart Block or Sick Sinus Syndrome (unless a permanent pacemaker is in place).
• Known hypersensitivity to the medicine or its components.

Restricted and Conditional Use

• Pediatric Use (under 18 years) is officially not established for standard indications.
• Pregnancy status is conditional; use is restricted to instances where the potential benefit justifies the potential risk, as safety is not established. Use during Lactation is not recommended.
• Patients with Diabetes Mellitus or Renal Impairment require close medical monitoring and caution, as the medicine may mask signs of hypoglycemia or impact renal function.

Official Regulatory Interaction Statements

The official interaction profile for Карведилол outlines specific pharmacokinetic and pharmacodynamic constraints for co-administration, as documented in government labeling.

Interactions Affecting Plasma Exposure

The co-administration of certain medicinal products can significantly modify the body's plasma exposure to Карведилол. Inducers of CYP enzymes, such as Rifampin, are documented to reduce Карведилол concentrations by approximately mathbf70%. Conversely, CYP2D6 inhibitors, including Fluoxetine and Paroxetine, or Cimetidine are reported to increase Карведилол exposure.

Карведилол may also affect co-administered drugs. It is documented to increase the trough concentrations of Cyclosporine, requiring dose reduction in some patients. Similarly, Digoxin exposure is increased by Карведилол, resulting in a mathbf14% increase in AUC (exposure).

Additive Pharmacodynamic Effects

The co-administration of Карведилол with other agents that slow heart rate or lower blood pressure carries officially described risks of additive effects. This applies to Digitalis Glycosides and Calcium Channel Blockers of the Verapamil or Diltiazem type, which pose an increased risk of severe bradycardia and AV conduction disturbance. Additive effects on blood pressure are also noted with other Hypotensive Agents.

Timing and Substance Requirements

Official regulatory labeling states that Карведилол must be taken with food to help mitigate the risk of orthostatic hypotension. Administration of Карведилол extended-release capsules with alcohol is restricted due to the potential for accelerated drug release. When ending co-treatment with Clonidine, Карведилол must be discontinued first.

Dual Adrenoreceptor Blockade and Myocardial Regulation

Carvedilol functions as a nonselective beta-adrenoreceptor antagonist (beta1 and beta2) and a selective alpha1-adrenoreceptor antagonist. The beta1 blockade primarily occurs in the myocardium, where it prevents the binding of catecholamines (e.g., norepinephrine). This antagonism reduces intracellular cAMP and calcium flux, resulting in negative chronotropy (slowing the heart rate) and negative inotropy (reducing contractile force). This action modulates processes associated with excessive neurohormonal activation.

Vascular Modulation and Hemodynamic Synergy

,alpha1-Antagonism targets vascular smooth muscle, promoting the relaxation of the vessel walls and initiating vasodilation. This mechanism reduces total peripheral vascular resistance (afterload), which, combined with the cardiac effects, leads to a reduction of overall myocardial load. This combined beta/alpha1 blockade creates a synergistic hemodynamic effect by modulating both cardiac output and systemic vascular resistance simultaneously.

Independent Antioxidant Pathway

Beyond receptor antagonism, Carvedilol possesses non-adrenergic properties, acting as a direct antioxidant by scavenging free radicals. This mechanism exerts a stabilizing effect on cellular membranes and reduces oxidative stress within cardiac tissue. This modulates pathways associated with cellular damage and pathological myocardial remodeling.

Carvedilol is an oral medication available as Immediate-Release (IR) tablets and Extended-Release (ER) capsules. The IR tablets are generally administered twice daily, while the ER capsules follow a once daily frequency pattern. The foundational principle of use is slow, gradual dose titration.

Administration Principle: Titration

Treatment is initiated with a low initial dose (e.g., 3.125 mg twice daily for heart failure) and is progressively increased over fixed intervals, usually not less than two weeks, until the target maintenance dose is achieved. This structured titration is a standard component of the use protocol for chronic conditions. If a dose is missed, it is generally instructed to take the next dose at the regularly scheduled time, rather than doubling the dose.

Timing and Special Handling

A key administration rule is that the Immediate-Release tablets must be taken with food to modulate absorption. Conversely, the Extended-Release capsules must be swallowed whole and should not be crushed, chewed, or divided. Carvedilol is intended for long-term, chronic management. If use must be stopped, it must not be discontinued abruptly; instead, a gradual dose reduction (tapering) over a period of 1 to 2 weeks is required. While dose adjustment is not typically required for older adults, safety and efficacy are not established in pediatric patients.

Research evidence / Overview of Studies for Carvedilol (Карведилол)

This section provides a descriptive summary of the research that has been conducted on Carvedilol. The information below details the specific populations studied and the measurements reported by researchers, and it is not intended to be clinical advice or a statement on individual treatment suitability.

Evidence for use in Chronic Heart Failure (Mild-to-Severe)

The research foundation for Carvedilol in heart failure largely stems from large-scale Randomized Controlled Trials (RCTs). These studies included adults with mild-to-severe symptomatic Chronic Heart Failure, particularly those with reduced Left Ventricular (LV) function, who were already receiving other standard foundation treatments. Researchers primarily monitored long-term endpoints, including all-cause mortality and the frequency of hospitalization specifically related to heart failure. The studies also explored how the condition evolved in the observed populations by measuring changes in cardiac function and patient-reported outcomes describing perceived discomfort.

Evidence for use following Myocardial Infarction

Carvedilol was also evaluated in large, event-driven survival trials involving clinically stable adults who had recently survived a heart attack. The research examined outcomes in those who had developed Left Ventricular Dysfunction (a condition marked by reduced pumping function). The studies monitored primary endpoints, including all-cause mortality and the incidence of non-fatal cardiovascular events. The findings reported apply to this specific population defined by the presence of LV dysfunction post-MI.

Evidence for use in Essential Hypertension (High Blood Pressure)

The research base for high blood pressure includes RCTs that compared Carvedilol against a placebo or against other established medications. The studies primarily examined outcomes related to systemic or functional imbalance by measuring the degree of change in systolic and diastolic blood pressure over observation periods lasting several weeks or months. These trials reported measurements showing a change in blood pressure in the observed populations.

What is Still Uncertain About the Research

Research highlights what is known and what is still uncertain across the evidence base. Some limitations noted include the fact that comparative evidence is lacking against every alternative treatment option. For the hypertension indication, evidence quality varies across studies, and there is not the same depth of large-scale, long-term RCTs focusing on cardiovascular event reduction as exists for heart failure.

Common questions about Карведилол (FAQ)

Q: How quickly does Карведилол start to work?

According to official product information, the initial heart rate-slowing effect of Carvedilol (its beta-adrenoreceptor blocking activity) is typically seen within 1 hour of administration. Achieving the full intended effect for chronic conditions may take several weeks, aligning with the mandated protocol for gradual dose adjustment.

Q: Can Карведилол affect my ability to drive or operate machinery?

Official regulatory information warns that Carvedilol may cause side effects like dizziness, lightheadedness, or fatigue, particularly when treatment begins or the dose is adjusted. Regulatory information advises that patients avoid driving or operating heavy machinery until they are aware of their personal response to the medication.

Q: What is the difference between Карведилол and Metoprolol?

Carvedilol is a third-generation, dual-acting blocker that affects both beta and alpha-1 receptors, allowing it to modulate both heart rate and blood vessel widening. Metoprolol, on the other hand, is generally classified as a beta-1 selective blocker at standard doses and lacks the alpha-1 blocking effect.

Q: What common over-the-counter pain relievers can interact with Карведилол?

Official drug labeling indicates that nonsteroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen, can potentially reduce the effectiveness of Carvedilol in lowering blood pressure. The co-administration of these types of drugs may necessitate medical review of blood pressure.

Q: What is the long-term safety profile of Карведилол?

Studies and official information indicate that Carvedilol is intended for long-term, chronic management. Long-term clinical trials focusing on heart failure populations have examined outcomes including mortality and hospitalization rates. The safety profile includes common, monitored effects like dizziness, fatigue, and slow heart rate.

Q: What should I know about taking Карведилол before surgery?

Official regulatory guidance advises that the decision regarding continuing Carvedilol through the day of elective surgery be made by a healthcare professional. Abruptly stopping the drug is advised against because of the risk of rebound effects, such as a sharp increase in blood pressure or heart symptoms. The medical team should be informed that the medication is being taken.

Q: Can I take cold medicine while using Карведилол?

Regulatory warnings indicate that caution should be exercised when taking Carvedilol with cold or flu medicines that contain sympathomimetic agents (a class of stimulants often found in decongestants). These agents can potentially increase heart rate and blood pressure, which may counteract the intended therapeutic effect of Carvedilol.

Q: Is Карведилол described as a drug for both high blood pressure and angina?

Yes, according to official regulatory labeling, Carvedilol is listed as an approved indication for the treatment of essential hypertension (high blood pressure). It is also indicated for the management of angina pectoris (chest pain).

Q: Does Карведилол have any effect on cholesterol levels?

Studies have observed that Carvedilol may have a neutral or potentially favorable impact on certain metabolic markers, including cholesterol and triglyceride levels.

Q: Does smoking affect how well Карведилол works?

Official information suggests that smoking may interfere with the intended therapeutic effect of Carvedilol. Since nicotine is a stimulant that increases heart rate and blood pressure, it can potentially counteract the actions of Carvedilol, and any change in smoking status may require a re-evaluation of the treatment plan.

Q: Can Карведилол cause issues with sleep?

Official safety documentation lists sleep disturbance as a possible side effect of Carvedilol. This can include difficulty falling asleep or staying asleep.

Q: Is a metallic taste in the mouth sometimes linked to Карведилол?

While not a common effect, official regulatory documents have included reports of an altered taste sensation in the mouth among the less frequently reported side effects. This is a rare occurrence where the exact incidence rate is not known.

Q: Does the brand name of Карведилол matter, or is the generic the same?

Carvedilol is approved by regulatory agencies and is widely available in generic form. To achieve regulatory approval, generic formulations must demonstrate bioequivalence to the brand-name product.

Q: Are there any official restrictions on consuming caffeine with Карведилол?

Caution is generally advised regarding the consumption of excessive caffeine while taking Carvedilol. Since caffeine acts as a stimulant, it can potentially interfere with the drug's effects to lower heart rate and blood pressure.

Q: What patient information is available from the NIH about Карведилол?

The U.S. National Institutes of Health (NIH) provides extensive, reliable patient information about Carvedilol, including its uses, side effects, and how it works in the body. This information is available through resources such as MedlinePlus and PubMed Central.

Official Storage Conditions

Carvedilol tablets must be stored at Controlled Room Temperature, which is defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The product requires protection from both moisture and light and must be kept in a tight, light-resistant container.

Handling and Child Safety

This medication must be stored out of the reach and sight of children. If the contents of the extended-release capsule are mixed with food for administration, the mixture must be consumed immediately and should not be stored for later use.

Disposal Requirements

Unused, expired, or waste Carvedilol product must be disposed of in accordance with local legal requirements for pharmaceutical waste. The product should be safely thrown away following regulatory procedures.